Dark Forest Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Dark Forest Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$892K	Sell	18,756 -1,183	-6%	-$62.4K	0.08%	403
2025 Q4	$1.05M	Buy	+19,939	New	+$1.19M	0.05%	632
2022 Q1	–	Sell	-160	Closed	-$12K	–	1362
2021 Q4	$12K	Buy	+160	New	+$14K	﹤0.01%	857
2021 Q3	–	Sell	-217	Closed	-$35K	–	1310
2021 Q2	$35K	Buy	+217	New	+$26.4K	0.02%	493

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dark Forest Capital Management's CRSP Position: Q1 2026 in Review

Dark Forest Capital Management reduced its CRISPR Therapeutics (CRSP) stake by 5.9% in Q1 2026, selling an estimated $62.4K and leaving 18,756 shares worth $892K. The position accounts for 0.08% of the portfolio, ranked #403.

Dark Forest Capital Management first reported a position in CRSP in Q2 2021 and has held it in 4 quarters since. The position peaked at $1.05M in Q4 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Dark Forest Capital Management held 18,756 shares of CRISPR Therapeutics worth $892K as of Q1 2026.
Dark Forest Capital Management sold 1,183 CRISPR Therapeutics shares in Q1 2026, an estimated $62.4K.
CRISPR Therapeutics made up 0.08% of Dark Forest Capital Management's portfolio in Q1 2026, its #403 holding.
Dark Forest Capital Management first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 4 quarters since.
Dark Forest Capital Management's CRISPR Therapeutics position peaked at $1.05M in Q4 2025.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Dark Forest Capital Management's 13F filing for Q1 2026, filed 15 May 2026.